Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 632

Results For "ENT"

9413 News Found

India achieves 15,000+ transplants in a year
News | February 20, 2023

India achieves 15,000+ transplants in a year

There is a fast resurgence in the transplant activities post COVID


USFDA accepts for priority review the sNDA for Merck’s Prevymis
Drug Approval | February 18, 2023

USFDA accepts for priority review the sNDA for Merck’s Prevymis

FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients


Asahi Kasei completes construction of microcrystalline cellulose plant
News | February 18, 2023

Asahi Kasei completes construction of microcrystalline cellulose plant

With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC


IAGES collaborates with technology leaders in robotic surgery
News | February 18, 2023

IAGES collaborates with technology leaders in robotic surgery

IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023


Garuda Aerospace and Narayana Health join hands to transport biomedical supplies using drone
News | February 18, 2023

Garuda Aerospace and Narayana Health join hands to transport biomedical supplies using drone

The partnership is announced at Aero India 2023, Bangalore


Pfizer announces Talzenna and Xtandi combination data from phase 3 study
News | February 18, 2023

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI


Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg
Drug Approval | February 18, 2023

Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg

Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)


Lupin receives EIR from USFDA for injectable facility in Nagpur
News | February 18, 2023

Lupin receives EIR from USFDA for injectable facility in Nagpur

The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022


AstraZeneca Pharma India receives no objection for Durvalumab
Drug Approval | February 17, 2023

AstraZeneca Pharma India receives no objection for Durvalumab

Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer


Briefs: Piramal Pharma, Alembic Pharmaceuticals
News | February 17, 2023

Briefs: Piramal Pharma, Alembic Pharmaceuticals

USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA